Chronic rhinosinusitis with nasal polyps (CRSwNP), Asthma with type 2 inflammation
GSKGSKCatalyst overview
Research summary
This catalyst tracks a Approved quarterly sales for Exdensur (depemokimab) in Chronic rhinosinusitis with nasal polyps (CRSwNP), Asthma with type 2 inflammation. The expected timing is based on the latest available company guidance and may change.
SWIFT-1 & SWIFT-2 (Asthma): 5/21/24- Positive Ph3 results. ANCHOR-1 & ANCHOR-2 (CRSwNP): 10/14/24- Positive Ph3 top-line data reported. 3/3/25- BLA accepted for both indications with PDUFA date December 16, 2025. 12/16/25:- US approved Exdensur for severe eosinophilic asthma; CHMP positive, EU approval expected Q1 2026.
Verification
Confirm timing and program details against the company announcement or filing.